Table A1.
Baseline Characteristics (caffeinated and decaffeinated coffee consumption) for 953 Participants
| Characteristic | Caffeinated Coffee Intake (cups/d) |
Decaffeinated Coffee Intake (cups/d) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| 0 (n = 238) | < 1 (n = 247) | 1 (n = 183) | 2-3 (n = 247) | ≥ 4 (n = 38) | 0 (n = 447) | < 1 (n = 301) | 1 (n = 94) | ≥ 2 (n = 81) | |
| Intake, cups/d | |||||||||
| Median | 0 | 0.1 | 1.0 | 2.5 | 4.5 | 0 | 0.1 | 1.0 | 2.5 |
| Range (min) | 0 | 0.0026 | 0.506 | 1.502 | 3.518 | 0 | 0.00007 | 0.513 | 1.576 |
| Range (max) | 0 | 0.4981 | 1.475 | 3.371 | 6.000 | 0 | 0.498 | 1.490 | 5.857 |
| Male sex, No. (%) | 114 (48) | 142 (58) | 98 (54) | 151 (61) | 29 (76) | 272 (57) | 151(50) | 57 (61) | 54 (67) |
| Age, years, median (range) | 57 (34-85) | 63 (21-82) | 60 (28-83) | 60 (26-79) | 57 (29-78) | 57 (21-82) | 60 (24-85) | 67 (36-80) | 66 (46-78) |
| Race, No. (%) | |||||||||
| White | 201 (84.5) | 210 (85.0) | 161 (88.0) | 237 (96.0) | 38 (100) | 429 (89.9) | 262 (87.0) | 80 (85.1) | 76 (93.8) |
| Black | 27 (11.3) | 22 (8.9) | 10 (5.5) | 2 (0.8) | 0 (0) | 25 (5.2) | 24 (8.0) | 10 (10.6) | 2 (2.5) |
| Other | 10 (4.2) | 15 (6.1) | 12 (6.6) | 8 (3.2) | 0 (0) | 23 (4.8) | 15 (5.0) | 4 (4.3) | 3 (3.7) |
| Baseline performance status, No. (%)* | |||||||||
| 0 | 170 (71.4) | 174 (70.4) | 138 (75.4) | 187 (75.7) | 27 (71.1) | 347 (72.7) | 220 (73.1) | 71 (75.5) | 58 (71.6) |
| 1-2 | 64 (26.9) | 69 (27.9) | 40 (21.9) | 53 (21.5) | 10 (26.3) | 118 (24.7) | 74 (24.6) | 22 (23.4) | 22 (27.2) |
| Status unknown | 4 (1.7) | 4 (1.6) | 5 (2.7) | 7 (2.8) | 1 (2.6) | 12 (2.5) | 7 (2.3) | 1 (1.1) | 1 (1.2) |
| Invasion through bowel wall by T stage, No. (%)† | |||||||||
| T1-2 | 47 (19.7) | 19 (7.7) | 25 (13.7) | 34 (13.8) | 5 (13.2) | 68 (14.3) | 36 (12.0) | 13 (13.8) | 13 (16.0) |
| T3-4 | 179 (75.2) | 212 (85.8) | 144 (78.7) | 193 (78.1) | 29 (76.3) | 370 (77.6) | 247 (82.1) | 77 (81.9) | 63 (77.8) |
| T stage unknown | 12 (5.0) | 16 (6.5) | 14 (7.7) | 20 (8.1) | 4 (10.5) | 39 (8.2) | 18 (6.0) | 4 (4.3) | 5 (6.2) |
| Positive lymph nodes, No. (%) | |||||||||
| 1-3 | 149 (62.6) | 158 (64.0) | 122 (66.7) | 146 (59.1) | 23 (60.5) | 302 (63.3) | 190 (63.1) | 58 (61.7) | 48 (59.3) |
| ≥ 4 | 84 (35.3) | 85 (34.4) | 56 (30.6) | 95 (38.5) | 15 (39.5) | 163 (34.2) | 105 (34.9) | 35 (37.2) | 32 (39.5) |
| Nodes unknown | 5 (2.1) | 4 (1.6) | 5 (2.7) | 6 (2.4) | 0 (0) | 12 (2.5) | 6 (2.0) | 1 (1.1) | 1 (1.2) |
| Grade of differentiation, No. (%) | |||||||||
| Well | 13 (5.5) | 16 (6.5) | 11 (6.0) | 14 (5.7) | 1 (2.6) | 32 (6.7) | 14 (4.7) | 5 (5.3) | 4 (4.9) |
| Moderate | 160 (67.2) | 181 (73.3) | 136 (74.3) | 155 (62.8) | 25 (65.8) | 321 (67.3) | 213 (70.8) | 69 (73.4) | 54 (66.7) |
| Poor/undifferentiated | 61 (25.6) | 45 (18.2) | 31 (16.9) | 71 (28.7) | 12 (31.6) | 111 (23.3) | 68 (22.6) | 19 (20.2) | 22 (27.2) |
| Grade unknown | 4 (1.7) | 5 (2.0) | 5 (2.7) | 7 (2.8) | 0 (0) | 13 (2.7) | 6 (2.0) | 1 (1.1) | 1 (1.2) |
| Clinical bowel obstruction at presentation, No. (%) | 52 (21.8) | 57 (23.1) | 34 (18.6) | 53 (21.5) | 10 (26.3) | 106 (22.2) | 66 (21.9) | 23 (24.5) | 11 (13.6) |
| Bowel perforation at presentation, No. (%) | 13 (5.5) | 10 (4.0) | 5 (2.7) | 8 (3.2) | 3 (7.9) | 22 (4.6) | 10 (3.3) | 6 (6.4) | 1 (1.2) |
| Treatment arm, No. (%) | |||||||||
| FU/LV | 120 (50.4) | 124 (50.2) | 100 (54.6) | 122 (49.4) | 20 (52.6) | 255 (53.5) | 156 (51.8) | 44 (46.8) | 31 (38.3) |
| IFL | 118 (49.6) | 123 (49.8) | 83 (45.4) | 125 (50.6) | 18 (47.4) | 222 (46.5) | 145 (48.2) | 50 (53.2) | 50 (61.7) |
| BMI, kg/m2, median (range)‡ | 27.6 (17.2-49.9) | 27.2 (16.3-46.2) | 27.3 (17.3-46.3) | 27.3 (15.7-51.8) | 26.5 (19.0-46.2) | 27.7 (15.7-49.9) | 26.8 (17.2-51.8) | 26.6 (17.2-49.4) | 27.4 (18.5-40.3) |
| Physical activity, MET-h/w, median (range)‡ | 4.0 (0-119.9) | 6.0 (0-147.4) | 3.9 (0-125.2) | 5.2 (0-114.2) | 13.2 (0-114.6) | 5.4 (0-147.4) | 4.5 (0-112.7) | 3.2 (0-87.5) | 6.9 (0-112.7) |
| Current smoker, No. (%)‡ | 17 (7.1) | 16 (6.5) | 14 (7.7) | 35 (14.2) | 12 (31.6) | 55 (11.5) | 23 (7.6) | 9 (9.6) | 7 (8.6) |
| Currently uses multivitamin, No. (%)‡ | 126 (52.9) | 131 (53.0) | 91 (49.7) | 105 (42.5) | 16 (42.1) | 209 (43.8) | 172 (57.1) | 50 (53.2) | 38 (46.9) |
| Dietary intake‡ | |||||||||
| Total energy, kcal/d | 1,761 (559-3,974) | 1,973 (650-3,902) | 1,938 (615-3,844) | 2,027 (618-4,100) | 2,329 (1,050-3,784) | 1,950 (559-4,100) | 1,951 (727-3,902) | 1,877 (685-3,891) | 1,978 (1,045-3,240) |
| Alcohol consumption, g/d | 0 (0-66.9) | 0.4 (0-67.0) | 0.6 (0-83.2) | 0.8 (0-93.0) | 1.2 (0-37.5) | 0 (0-93.0) | 0.6 (0-61.2) | 0.4 (0-35.2) | 0.4 (0-67.0) |
| Glycemic load | 151.7 (57.5-247) | 151.8 (88.9-231) | 144.8 (79.2-232) | 142.2 (80.1-204) | 137.2 (97.2-187) | 146.7 (57.5-231) | 147.2 (82.4-232) | 151.8 (99.8-247) | 147.2 (90.7-208) |
| Sugar-sweetened beverage, s/d | 0.4 (0-4.8) | 0.4 (0-5.4) | 0.3 (0-5.9) | 0.3 (0-5.1) | 0.4 (0-3.4) | 0.4 (0-5.4) | 0.3 (0-5.9) | 0.4 (0-3.6) | 0.2 (0-3.5) |
| Caffeine, mg/d | 36 (0-543) | 60 (2-593) | 165 (3-886) | 331 (2-1,376) | 542 (10-975) | 154 (0-1,376) | 117 (1-1,098) | 72 (2-637) | 64 (0-793) |
| Western dietary pattern, No. ≥ median (%)‡ | 97 (40.8) | 119 (48.2) | 81 (44.3) | 149 (60.3) | 30 (78.9) | 244 (51.2) | 143 (47.5) | 41 (43.6) | 48 (59.3) |
| Prudent pattern diet, No. ≥ median (%)‡ | 111 (46.6) | 135 (54.7) | 100 (54.6) | 120 (48.6) | 11 (28.9) | 231 (48.4) | 160 (53.2) | 46 (48.9) | 40 (49.4) |
Abbreviations: BMI, body mass index; FU/LV, fluorouracil and leucovorin; IFL, irinotecan, fluorouracil, and leucovorin; MET-h/w, metabolic equivalent task hours per week; min, minimum; max, maximum; s, servings.
*
Baseline performance status (PS): PS 0 indicates fully active; PS 1, restricted in physically strenuous activity but ambulatory and able to perform light work; PS 2, ambulatory and capable of all self-care but unable to perform any work activities, up and approximately more than 50% of waking hours.
†
T1-2 indicates level of invasion through the bowel wall not beyond the muscle layer; T3-4, level of invasion through the bowel wall beyond the muscle layer.
‡
As reported on questionnaire 1.